

Challenging bioanalytical work? We are ready to assist.

Leading with science for over three decades

Bringing a promising drug candidate to market requires a well-planned strategy incorporating sensitive, specific, and validated assays to inform development decisions. Our scientists apply leading-edge technologies, automated platforms, and state-of-the-art techniques to support a wide range of bioanalytical and ADME services.

From high-throughput ADME screening services to worldwide Phase III PK/ADA sample analysis, our global network offers solutions to help you at each step of the development process.

Our bioanalysis services include:



Liquid Chromatography Mass-Spectrometry (LC-MS) and High Resolution Mass-Spectrometry (HRMS) services for the quantitative determination of small molecule drugs and macromolecule therapeutics to support pharmacokinetic (PK) testing



Immunoassay services, including ELISA, MSD, ECL and neutralizing antibody assays to facilitate pharmacokinetic (PK) testing and immunogenicity testing



Biomarker assays using LC-MS analysis and ligand-binding assays to quantitate biomarkers in biological matrices



In vitro ADME screening assays and discovery/development metabolite identification services that enable rapid drug discovery, ADME property optimization, and regulatory filings

Turning Hope **Into Help**™

End-to-end drug development solutions

One lab partner to support your product throughout the development continuum

Discovery

Pre-clinical

Translational Phase I-III – RWLP

Commercial

Discovery Services

- · Candidate selection
- High throughput-ADME screening
- Discovery-level "hot-spot" metabolite ID
- Discovery-level bioanalysis with high throughput capabilities

Pre-clinical Services

- LC-MS, HRMS, and immunoassay
- · Immunogenicity
- LC-MS, HRMS, and immunoassay biomarkers
- Definitive IND-enabling ADME assay
- Cross-species metabolite ID
- Assay development

Clinical Phase I-III Services

- GCP-compliant
- · Immunogenicity
- LC-MS, HRMS, and immunoassay biomarkers
- Definitive ADME assays
- · Development metabolite ID
- Met ID radio-profiling
- Assay development and transfer to support large-scale studies

Phase IV Services

- GLP LC-MS, HRMS, and immunoassay
- Immunogenicity
- LC-MS, HRMS, and immunoassay biomarkers

Q² Solutions offers bioanalytical and ADME services around the globe

We serve many biotechnology, specialty, and large pharmaceutical companies in the world with scalable expertise and innovative solutions.



Ithaca, NY, USA1

- Preclinical/Clinical
- LC-MS, HRMS



RTP. NC. USA

- Preclinical/Clinical
- Immunoassay



Indianapolis, IN, USA²

- Preclinical/Clinical
- Bioanalytical and <u>ADME</u>
- LC-MS, HRMS, and Immunoassay



Beijing, China

- Clinical
- LC-MS and Immunoassay

¹lthaca lab expanded in 2023 ²lndianapolis lab expanded in 2024

We solve problems that have never been attempted before

As a leading drug discovery and development laboratory services organization, we specialize in solutions for bioanalysis and ADME. Q² Solutions also provides solutions for genomics, vaccines, antibody drug discovery and central laboratory services, including immunoassay testing, flow cytometry, anatomic pathology, molecular and companion diagnostics, and decentralized trials.

For the past 30 years, we've been a highly collaborative partner, delivering cutting-edge solutions and developing testing strategies (including early engagement), which maximizes your return on investment. Our team of scientific experts work side by side with you, complimenting your own internal knowledge and skill set, supporting your needs, and achieving milestone for your clinical development.



Scan to see how we're leading with science



Contact us

Website: www.Q2LabSolutions.com

Copyright ©2024 Q2 Solutions. All rights reserved. Q2-04.02.02.02-Mar2024

